Brazil’s Lima & Pergher hit with FDA warning letter; import ban in effect

FDA sign

Brazil’s Lima & Pergher was hit with an FDA warning letter in the wake of a February inspection that found significant violations at the company’s manufacturing facility.

The regulatory agency’s warning letter, issued Aug. 25, cited poor quality control that resulted in adulterated drugs coming out of the plant located in Uberlandia within the state of Minas Gerais in Brazil.

Specifically, the agency said the drugmaker failed to perform microbiological testing on each lot of finished product and had no stability data to support expiration dates on its drugs.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Additionally, inspectors noted that the facility’s raw material qualification process was inadequate for its drug products.

The FDA also recommended that Lima & Pergher hire a qualified consultant to get their factory in order.

The agency placed the company on its import alert list in July, effectively banning the company from distributing its drugs in the U.S.

- check out the warning letter

Related Articles:
Teva, Mylan eye Pfizer’s Brazil unit 
Brazil funds dengue vaccine PhIII, report says

Read more on

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.